What can I do for you
James is a partner in our corporate team, focussing on transactions in the technology and life sciences sectors. He has advised some of the world's leading companies on M&A, fundraisings, joint ventures and company law matters.
James has extensive cross-border expertise, having coordinated transactions and counsel across more than 50 jurisdictions. He has particular experience advising on transactions that involve US acquirers, having spent seven years in the London offices of two leading Silicon Valley law firms.
Supporting your ambitions
James has experience advising clients ranging from pre-incorporation founders to the world’s most valuable companies. He works with founders, boards and GCs to get the fundamentals right, acquire to grow and achieve high-value exits.
What do others say
James has built a reputation for being responsive, knowledgeable and user-friendly.
“You're a rock star. So impressed with your work and dedication the last several months. Reachable at insane hours, extremely well organized, thoughtful, and cool under pressure. Intelligent, quality work.” (NASDAQ CFO)
"James displayed exceptional expertise and dedication throughout the entire process. His in-depth knowledge of the legal landscape, particularly in the tech industry, was evident in the strategic guidance he provided." (Founder)
"James worked with us on several M&A deals... usually under enormous time pressure, but always with great service delivery and good humour. The strains of multi-jurisdictional issues and difficult counterparties were always met with creative solutions and a can-do attitude. " (General Counsel)
What else should you know
Career highlights include advising:
- Apple on its acquisition of a UK spinout
- Battery Ventures on its acquisition of Guardsquare
- Bavarian Nordic on its acquisition of global rights to two vaccines from GSK for €796 million
- Baylis Medical on the sale of its cardiology unit to Boston Scientific for $1.75 billion
- Contentsquare on its acquisition of Hotjar
- DMGT (as majority shareholder) on the IPO of Zoopla
- Kerecis on its sale to Coloplast for up to $1.3 billion
- Learnosity on its acquisition of Questionmark
- Liquid New Media on the sale of Reviews.io to AppHub
- Nasuni on its acquisition of Storage Made Easy
- Renalytix.AI on its £22.25 million IPO and AIM admission
- Screendragon on its growth equity investment from Kennet and Federated Hermes
- Snap on its acquisition of WaveOptics for $500M+
- Snyk on multiple acquisitions, including DeepCode, FossID and manifold.io
- Therachon on its sale to Pfizer for up to $810 million
